HPR10 Added Benefit and Revenues of Oncology Drugs Approved By the European Medicines Agency between 1995 and 2020

Abstract

Authors

F. Brinkhuis W.G. Goettsch A.K. Mantel-Teeuwisse L.T. Bloem

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×